|Day Low/High||0.07 / 0.08|
|52 Wk Low/High||0.07 / 2.97|
Analyst downgrades and mind-boggling P/E ratios do not matter in this current market.
Presentation will highlight additional analyses of the CHABLIS-SC1, Phase 3 clinical study of blisibimod
Presentation to highlight data from the CHABLIS-SC1, Phase 3 clinical study of blisibimod
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.